Regulatory Affairs: The IND, NDA, and Post-Marketing

Attend this virtual training course to learn about FDA regulations and expectations for the content, submission and review of INDs/NDAs, and the importance of regulatory strategy.

戻る Agenda

Regulatory Affairs: Part 1: The IND – Investigational New Drug

Session Chair(s)

Drusilla Scott, PhD, RAC

Vice President, Regulatory Affairs

Sobi, Inc., United States

Regulatory Affairs: Part 1: The IND – Investigational New Drug

Regulatory Affairs: The IND, NDA, and Post-Marketing

Regulatory Affairs: Part 1: The IND – Investigational New Drug

Session Chair(s)

Drusilla Scott, PhD, RAC

最新情報や機会を逃さないで